Key Takeaways
- • Oxford BioMedica's CEO Frank Mathias signaled openness to private equity acquisition under the right valuation and strategic terms, despite rejecting multiple unsolicited EQT approaches in early 2026, according to Financial Times reporting.
- • The UK-listed cell and gene therapy company declined a final approach from Swedish PE firm EQT in February 2026, but management indicated certain PE investors could provide financial flexibility and strategic support aligned with growth objectives.
- • Oxford BioMedica has demonstrated strong financial momentum, with solid revenue growth driven by expanding demand for outsourced biologics manufacturing and increased US market investment, positioning it as an attractive acquisition target.
- • The company operates as a contract development and manufacturing organisation specializing in viral vectors for cell and gene therapies, with focus areas in oncology and autoimmune treatments, leveraging its COVID-era AstraZeneca manufacturing partnership.
- • Management retains strategic flexibility on listing status, with Mathias noting that remaining public carries distinct advantages, suggesting any PE transaction would require compelling value creation rationale.
Summary
Oxford BioMedica, the UK-listed cell and gene therapy manufacturer, has signaled conditional receptiveness to private equity acquisition despite a recent rejection of multiple unsolicited bids from Sweden's EQT. Chief Executive Frank Mathias told Financial Times that the company would evaluate PE approaches meeting specific valuation and strategic criteria, even as the organization weighed the benefits of maintaining its public market status.
The openness to PE interest comes following EQT's final approach in February 2026, which Oxford BioMedica declined. However, Mathias indicated that certain PE investors could enhance the company's development trajectory by offering enhanced financial flexibility and strategic backing. His comments suggest management views PE not as categorically undesirable but rather as contingent on alignment with long-term growth objectives and financial expectations.
Founded as a spinout from the University of Oxford in 1995, Oxford BioMedica gained significant visibility during the COVID-19 pandemic through its manufacturing partnership with AstraZeneca. The company has since repositioned as a specialized contract development and manufacturing organisation focusing on viral vectors deployed in cell and gene therapies, with therapeutic concentration in oncology and autoimmune indications. This positioning has proven commercially resilient, with the company reporting strong revenue growth underpinned by rising demand for outsourced biologics manufacturing and sustained US market expansion.
The company's recent financial and operational performance—including solid revenue growth and strong share price appreciation over the preceding twelve months—enhances its attractiveness to financial sponsors. This combination of established commercial traction, specialized manufacturing capabilities, and growth momentum creates a compelling investment thesis, potentially explaining both EQT's repeated bidding interest and management's conditional openness to PE structures despite preferring to retain public market optionality.
The openness to PE interest comes following EQT's final approach in February 2026, which Oxford BioMedica declined. However, Mathias indicated that certain PE investors could enhance the company's development trajectory by offering enhanced financial flexibility and strategic backing. His comments suggest management views PE not as categorically undesirable but rather as contingent on alignment with long-term growth objectives and financial expectations.
Founded as a spinout from the University of Oxford in 1995, Oxford BioMedica gained significant visibility during the COVID-19 pandemic through its manufacturing partnership with AstraZeneca. The company has since repositioned as a specialized contract development and manufacturing organisation focusing on viral vectors deployed in cell and gene therapies, with therapeutic concentration in oncology and autoimmune indications. This positioning has proven commercially resilient, with the company reporting strong revenue growth underpinned by rising demand for outsourced biologics manufacturing and sustained US market expansion.
The company's recent financial and operational performance—including solid revenue growth and strong share price appreciation over the preceding twelve months—enhances its attractiveness to financial sponsors. This combination of established commercial traction, specialized manufacturing capabilities, and growth momentum creates a compelling investment thesis, potentially explaining both EQT's repeated bidding interest and management's conditional openness to PE structures despite preferring to retain public market optionality.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.